Human cross-presentation infrastructure for immunotherapy
CrossRelay™ is a platform built to improve antigen validation, ex vivo CD8 T-cell priming, and APC-enabled immune engineering.
Most immunotherapy technologies focus on antigen discovery, antigen delivery, or effector-cell engineering. CrossRelay addresses a different bottleneck: reliable human antigen presentation.
Immunotherapy still depends on a weak link: human antigen presentation
Conventional MoDC
Variable differentiation, limited cross-presentation, and inconsistent functional potency.
Artificial APC systems
Useful in selected workflows, but incomplete as human antigen-presenting surrogates.
Endogenous DC dependence
Many vaccine and antigen workflows still rely on impaired or uncontrolled host APC function.
A platform designed around the biology that matters
Cross-presentation capability
Built to support antigen presentation workflows directly relevant to CD8 immunity.
CD8 priming utility
Designed for ex vivo activation, expansion, and evaluation of antigen-specific cytotoxic T-cell responses.
Platform scalability
Structured as a repeatable human APC infrastructure layer, not a one-off assay.
Commercial flexibility
Applicable to discovery services, immune validation, and future therapeutic programs.
Built as a platform, not a single product
CrossRelay Discover
Antigen and neoantigen validation workflows
CrossRelay Prime
Ex vivo CD8 T-cell priming workflows
CrossRelay Validate
APC benchmarking and immune potency workflows
CrossRelay Therapeutics
Future APC-enabled therapeutic programs
Where CrossRelay can create value
Neoantigen Programs
Improve the bridge between computational prediction and functional immune relevance.
T-cell Therapy Enablement
Support ex vivo priming, expansion, and evaluation workflows for cell-therapy programs.
Immune Assay Development
Provide a more informative human APC layer for potency, mechanism, and comparative studies.
Translational Immunology
Enable cross-presentation-centric research, benchmarking, and platform validation.
Why cross-presentation matters
Partner with CrossRelay
Evaluation studies
Assess CrossRelay fit in a specific workflow.
Pilot collaborations
Structured early projects for translational programs.
Platform partnerships
Deeper integration into internal immunology workflows.
Strategic discussions
Co-development and platform expansion conversations.
Products and services built on the CrossRelay platform
CrossRelay Discover
Evaluate candidate antigens in human APC-driven systems relevant to CD8 immunity and translational decision-making.
• Candidate antigen prioritization
• Neoantigen validation support
• Functional ranking workflows
CrossRelay Prime
Support generation, expansion, and assessment of antigen-specific cytotoxic T-cell responses in APC-enabled systems.
• Ex vivo priming workflows
• Antigen-specific response generation
• Cell therapy support studies
CrossRelay Validate
Compare, qualify, and optimize antigen-presentation systems and related assay inputs for translational use.
• APC benchmarking
• Comparative assay development
• Potency and mechanism support
CrossRelay Therapeutics
Longer-term expansion into therapeutic programs built on the platform’s cross-presentation and immune-priming logic.
• Platform extension
• APC-enabled programs
• Future pipeline development
How partners can engage
CrossRelay can be explored through evaluation studies, pilot projects, workflow design discussions, and broader platform partnership conversations.
Science grounded in human cross-presentation biology
Why antigen delivery is not enough
Antigen discovery and delivery technologies have improved dramatically, but strong CD8 immunity still depends on the ability of professional APCs to process and present exogenous antigen in functionally relevant ways.
Why cDC1-like function matters
Cross-presenting APC biology is closely linked to effective CD8 activation. Systems that better approximate this functional logic may offer more informative translational outputs than conventional MoDC workflows alone.
Why prior approaches were limited
Historical dendritic-cell methods have often been constrained by variability, limited cross-presentation capacity, and manufacturing inconsistency.
How CrossRelay should be evaluated
Cross-presentation performance, CD8 priming utility, reproducibility across donors and workflows, and comparative benchmarking against conventional APC systems are core evaluation axes.
Building a stronger APC layer for immunotherapy
Mission
Build enabling infrastructure for antigen validation, ex vivo CD8 priming, and APC-enabled immune engineering.
Why now
Immunotherapy has advanced rapidly in antigen prediction, delivery technologies, and effector-cell engineering. Human antigen presentation remains underbuilt as a platform layer.
Commercial model
CrossRelay is being developed as a platform business with multiple pathways, including productized workflows, translational services, and future APC-enabled therapeutic expansion.
Start a conversation with CrossRelay
Collaboration pathways
Evaluation studies
Assess CrossRelay fit in a specific antigen validation, T-cell priming, or APC benchmarking workflow.
Pilot collaborations
Structured early projects for teams exploring platform use in translational programs.
Platform partnerships
Deeper integration of CrossRelay into internal immunology, cell therapy, or assay-development programs.
Strategic discussions
Conversations around co-development, platform expansion, and future APC-enabled product strategy.
Tell us about your workflow or program
Use this form for product access, evaluation studies, pilot collaborations, and strategic partnership discussions.